Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


  • Karen Schow Jensen
  • Trausti Oskarsson, Karolinska Institutet, Sverige
  • Päivi Maria Lähteenmäki, University of Turku, Karolinska Institutet, Finland
  • Trond Flaegstad, UiT The Arctic University of Norway, Norge
  • Ólafur Jónsson, Landspitali University Hospital, Island
  • Petter Svenberg, Karolinska Institutet, Sverige
  • Kjeld Schmiegelow, Københavns Universitet
  • ,
  • Mats Heyman, Karolinska Institutet
  • ,
  • Ulrika Norén-Nyström, Umeå University, Sverige
  • Henrik Schrøder
  • ,
  • BK Albertsen

Relapse remains the main obstacle to curing childhood acute lymphoblastic leukemia (ALL). The aims of this study were to compare incidence of relapse, prognostic factors, and survival after relapse between three consecutive Nordic Society of Pediatric Hematology and Oncology trials. Relapse occurred as a primary event in 638 of 4 458 children (1.0–14.9 years) diagnosed with Ph-negative ALL between 1992 and 2018. The 5-year cumulative incidence of relapse was 17.3% (95% CI 15.4–19.2%) and 16.5% (95% CI 14.3–18.8%) for patients in the ALL1992 and ALL2000 trials, respectively, but decreased to 8.4% (95% CI 7.0–10.1%) for patients in the ALL2008 trial. No changes in duration of first complete remission and site of relapse were observed over time; however, high hyperdiploidy, and t(12;21) decreased in the ALL2008 trial. The 4-year overall survival after relapse was 56.6% (95% CI 52.5–60.5%) and no statistically significant temporal improvements were observed. Age ≥10 years, T-cell immunophenotype, bone-marrow involvement, early and very early relapse, hypodiploidy, and Down syndrome all independently predicted worse outcome after relapse. Improvements in the primary treatment of childhood ALL has resulted in fewer relapses. However, failure to improve outcome of remaining relapses suggests a selection of harder-to-cure relapses and calls for new therapeutic strategies.

Sider (fra-til)1274-1282
Antal sider9
StatusUdgivet - maj 2022

Se relationer på Aarhus Universitet Citationsformater

ID: 261197929